Search

391 Result(s)
Sort by

FDA approval NexGard PLUS for dogs

FDA approval NexGard PLUS for dogs

Boehringer Ingelheim Receives FDA Approval for NexGard® PLUS - A Beef-Flavored Soft Chew That Protects Dogs from Internal and External Parasites
Stroke symptoms

Stroke symptoms

The Angels initiative, stroke symptoms, giving life a chance, optimizing stroke care
Boehringer acquires T3 Pharma

Boehringer acquires T3 Pharma

Boehringer Ingelheim expands immuno-oncology portfolio with the acquisition of bacterial cancer therapy specialist T3 Pharma
Immuno-Oncology

Immuno-Oncology

We are developing complementary platforms (including, T Cell Engagers, oncolytic viruses, and cancer vaccines), which have the potential to turn cold tumors hot, extending the benefits of immunotherapy to more people.
Our Partners_ViraTherapeutics

Our Partners_ViraTherapeutics

Lisa Egerer, COO and Patrik Erlman, Head of Research at ViraTherapeutics talk about their partnering journey with Boehringer Ingelheim.
Interview with Michael Schmelmer

Interview with Michael Schmelmer

"You can work on initiatives that can improve treatment, provision, and early disease detection"", Michael Schmelmer, Member of the Board of Managing Directors
Spesolimab Phase II data

Spesolimab Phase II data

New data published in NEJM shows spesolimab improved signs & symptoms of GPP flares
PRRS Research Award 2022

PRRS Research Award 2022

Bridging science and veterinary practice for swine health: The winners of the European PRRS Award 2022
FIBRONEER™ Phase III program initiated

FIBRONEER™ Phase III program initiated

FIBRONEER™ Phase III program initiated globally to evaluate BI 1015550, a novel investigational phosphodiesterase 4B (PDE4B) inhibitor
Reggie the Red Blood Cell

Reggie the Red Blood Cell

Join Reggie, our curious red blood cell, on a journey exploring connections between the heart, kidneys and pancreas.